Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Total Liabilities: 2009-2024

Historic Total Liabilities for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Dec 2024 value amounting to $36.2 million.

  • Lineage Cell Therapeutics' Total Liabilities rose 116.49% to $68.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.8 million, marking a year-over-year increase of 116.49%. This contributed to the annual value of $36.2 million for FY2024, which is 7.15% down from last year.
  • As of FY2024, Lineage Cell Therapeutics' Total Liabilities stood at $36.2 million, which was down 7.15% from $39.0 million recorded in FY2023.
  • Lineage Cell Therapeutics' 5-year Total Liabilities high stood at $83.6 million for FY2021, and its period low was $12.8 million during FY2020.
  • Its 3-year average for Total Liabilities is $42.3 million, with a median of $39.0 million in 2023.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Total Liabilities spiked by 552.37% in 2021 and then slumped by 38.16% in 2022.
  • Yearly analysis of 5 years shows Lineage Cell Therapeutics' Total Liabilities stood at $12.8 million in 2020, then soared by 552.37% to $83.6 million in 2021, then slumped by 38.16% to $51.7 million in 2022, then fell by 24.61% to $39.0 million in 2023, then fell by 7.15% to $36.2 million in 2024.